Association between selective serotonin reuptake inhibitors and mortality following COVID-19 among patients with Alzheimer's disease.

ABSTRACT:

Background

Recent research suggests that selective serotonin reuptake inhibitors (SSRIs) may reduce mortality in COVID-19 patients; however, research into their benefits for elderly Alzheimer's disease (AD) patients remains limited.

Objective

To investigate the relationship between SSRIs therapy and the mortality risk after COVID-19 infection in elderly patients with and without AD.

Methods

This retrospective cohort study leveraged a large database containing over 100 million electronic health records in the US from the TriNetX platform to compare the hazard rates of mortality after COVID-19 infection in elderly AD patients prescribed SSRIs versus propensity-score matched individuals prescribed other antidepressants. This study was also conducted in separate cohorts o

SUBMITTER: Gao Z 

PROVIDER: S-EPMC12365858 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature